

Edgar Filing: GERON CORP - Form 8-K

GERON CORP
Form 8-K
December 19, 2007

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of Earliest Event Reported): December 18, 2007

GERON CORPORATION
(Exact name of registrant as specified in its charter)

Delaware	0-20859	75-2287752
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

230 CONSTITUTION DRIVE
MENLO PARK, CALIFORNIA 94025
(Address of principal executive offices, including zip code)

(650) 473-7700
(Registrant's telephone number, including area code)

N/A
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Compensatory Arrangements of Certain Officers

On December 18, 2007, the Compensation Committee (the "Committee") of the Board of Directors (the "Board") of Geron Corporation (the "Company") approved (a) increases in annual base salaries for 2008 and (b) cash performance bonuses for 2007 for the following principal executive officer, principal financial officer and named executive officers of the Company:

Edgar Filing: GERON CORP - Form 8-K

Name and Position	2008 Salary Increase	New 2008 Base Salary	2007 Cash Bonus
Thomas B. Okarma, Ph.D., M.D. President and CEO	\$25,000	\$535,000	\$275,000
Alan B. Colowick, M.D., M.P.H. President, Oncology	\$20,000	\$445,000	\$172,000
David L. Greenwood Executive Vice President and CFO	\$20,000	\$415,000	\$160,000
David J. Earp, Ph.D., J.D. Senior Vice President, Bus. Dev. and Chief Patent Counsel	\$15,000	\$325,000	\$112,000
Melissa Kelly Behrs Senior Vice President, Oncology	\$15,000	\$320,000	\$110,000
Jane L. Lebkowski, Ph.D. Senior Vice President, Regenerative Medicine	\$15,000	\$335,000	\$115,000
Calvin B. Harley, Ph.D. Chief Scientific Officer	\$10,000	\$315,000	\$83,000

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

GERON CORPORATION

Date: December 19, 2007

By: /s/ Thomas B. Okarma

Thomas B. Okarma
President and
Chief Executive Officer